CNS Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNSP research report →
Range $0.5 – $0.5
Price Chart
About the company
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
- CEO
- Rami Levin
- IPO
- 2019
- Employees
- 8
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on CNSP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.25M
- P/E
- -0.25
- Fwd P/E
- 1.56
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 3.00
- EV/EBITDA
- 0.66
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -166.03%
- ROIC
- -103.96%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-15,986,559
- Net Income
- $-15,850,564-6.7%
- EPS
- $-35.75+92.3%
- OCF Growth
- +19.3%
- FCF Growth
- +19.2%
- 52W High
- $10.54
- 52W Low
- $1.90
- 50D MA
- $4.82
- 200D MA
- $4.44
- Beta
- 1.01
- RSI (14)
- 45
- Avg Volume
- 9.41K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CNS Pharmaceuticals said it is on track to start Berubicin trials in 2020, with enough cash to fund operations into about mid-2021 but likely needing more capital to finish the Phase 2 program.· March 12, 2020
- Berubicin remains the lead asset, with FDA feedback already received on the pre-IND path and Phase 2 initiation targeted for the second half of 2020.
- The company highlighted a prior Berubicin Phase 1 study that showed a 44% response rate in 25 patients, including two partial responses and one durable complete response.
- CNS ended 2019 with $7.2 million in cash after its IPO and said that supports runway into approximately mid-2021.
- Management said the total Phase 2 trial cost is expected to be $8 million to $13 million, and up to $7 million of additional funding may be needed.
- A second program, WP1244, was added to the pipeline, and preclinical work is expected to begin by the end of 2020.
CNS did not provide full revenue or EPS figures on this call. Fourth-quarter 2019 general and administrative expense was $1.0 million versus $0.2 million in the prior-year period, and research and development expense was $1.5 million versus $0 in the prior-year period. The company said the fourth quarter included $0.3 million of non-cash stock-based compensation, and net cash used in the fourth quarter was $6.3 million. As of December 31, 2019, cash and cash equivalents were $7.2 million, including $8.8 million in net IPO proceeds. Forward-looking, management said it expects to begin the U.S. Phase 2 Berubicin study, the Poland Phase 2 study, and the Poland pediatric Phase 1 study in the second half of 2020, pending FDA approval of the IND. The company also said its cash runway extends to approximately mid-2021, that Phase 2 trial costs are expected to total $8 million to $13 million, and that up to $7 million of additional funding may be required.
John Climaco framed the call around the company’s progress since its IPO four months earlier, emphasizing pipeline expansion, positive FDA feedback, and GMP manufacturing progress. He focused heavily on Berubicin’s potential in glioblastoma, citing the disease’s poor prognosis and the drug’s possible ability to cross the blood-brain barrier, and he highlighted 2020 as a catalyst-rich year with trial starts and orphan drug designation as key milestones. His tone was upbeat and development-focused, with a strong emphasis on execution.
Chris Downs focused on the company’s cash position and the cost structure tied to getting Berubicin into the clinic. He said CNS raised $9.8 million in gross IPO proceeds, had $7.2 million in cash at December 31, 2019, and believes that balance gives the company runway into approximately mid-2021. He also laid out the financial burden of development, saying the Phase 2 trial should cost $8 million to $13 million, that up to $7 million more may be needed, and that annual G&A cash burn is expected to be approximately $2.5 million to $3.0 million.
There was no substantive analyst Q&A on the call; the operator closed the line without taking questions. The only additional management commentary came after the prepared remarks, when John Climaco mentioned the upcoming virtual ROTH Conference and availability for investor meetings on March 16 and 17.
The bull case is that CNS has already received favorable FDA feedback on its pre-IND strategy and says it is moving toward multiple Berubicin trial starts in 2020. Management also pointed to prior Phase 1 data showing a 44% response rate and added a second brain-cancer asset, WP1244, which could broaden the platform and support combination approaches.
The main risk is financing: the company said Phase 2 could cost $8 million to $13 million and that it may need up to $7 million of additional funding despite a cash balance of $7.2 million at year-end. Execution also depends on IND approval and timely trial start-up, and the company acknowledged that much of the 2019 spending was front-loaded manufacturing and validation work needed before studies can begin.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.2%
- Shares Outstanding
- 1.48M
- Float Shares
- 1.32M
of shares held by institutions
11 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ikarian Capital, LLC | 135.83K | 0 |
| Adar1 Capital Management, LLC | 70.00K | 0 |
| Stonepine Capital Management, LLC | 39.94K | ▼ 1.63K |
| Citadel Advisors LLC | 19.70K | ▲ 19.70K |
| Vanguard Capital Management LLC | 15.76K | ▲ 8.77K |
| Boothbay Fund Management, LLC | 13.52K | 0 |
| Vanguard Fiduciary Trust Co | 10.23K | 0 |
| Tower Research Capital LLC (Trc) | 150 | ▼ 649 |
| Ubs Group AG | 130 | ▼ 1.33K |
| Fmr LLC | 26 | ▲ 26 |
| Barclays PLC | 1 | ▼ 18 |
| Danske Bank A/S | 1 | 0 |
Held by 5 ETFs
Biggest fund positions in CNSP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Fisher Michal | buy | 2,000 |
| May 4, 26 | Fisher Michal | other | 0 |
| Aug 14, 26 | Levin Rami | other | 4,750 |
| Aug 14, 26 | Levin Rami | other | 4,750 |
| May 18, 26 | Charles Faith L. | buy | 7,100 |
| Mar 2, 26 | Faulkner Eric | other | 9,500 |
| Mar 2, 26 | Faulkner Eric | other | 0 |
| Mar 2, 26 | O'Loughlin Steve | other | 9,500 |
| Mar 2, 26 | O'Loughlin Steve | other | 0 |
| Jan 1, 26 | Levin Rami | other | 19,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNSP coverage
Recent articles, reports, and earnings notes.
No research on CNSP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNSP report →CNS Pharmaceuticals (NASDAQ:CNSP) Stock Jumps 1.5% – Here’s Why
defenseworld.net · Oct 4
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com · Sep 30
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
accessnewswire.com · Sep 1
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
accessnewswire.com · Aug 27
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
accessnewswire.com · Aug 12
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
accessnewswire.com · Jun 8
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
accessnewswire.com · May 20
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
247wallst.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.